Biotech

All Articles

Ideaya bags possibility on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is betting $400 thousand in biobucks that a bispecific antibody-drug conjugate (...

Takeda takes $140M loss on stopped working epilepsy medicine, boasts FDA operate

.Our team currently recognize that Takeda is hoping to discover a course to the FDA for epilepsy med...

VBI Vaccinations files for insolvency, seeks possession purchase

.Immunology biotech VBI Injections is diverting hazardously close to the moment of truth, with strat...

Celldex anti-cKIT antibody reduce hives in yet another stage 2 research

.It is actually hard to muscular tissue in on a room as competitive as immunology, but Celldex Thera...

Boehringer provides to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is actually offering up to $1.3 billion for Nerio Rehabs and a preclinical imm...

Ventyx's last hope for inflamed med ends in Crohn's failing

.Ventyx Biosciences' Crohn's disease medication did not assist individuals attain remission in a sta...

Cognition's period 2 beam data stain Alzheimer's prospect

.Knowledge Therapies' stage 2 luster trial has actually taken some of the luster off the Alzheimer's...

BMS axes bispecific months after filing to work phase 3 test

.Bristol Myers Squibb has had a whiplash change of mind on its own BCMA bispecific T-cell engager, s...

Charles Baum manages Terremoto as CEO

.Charles Baum, M.D., Ph.D., that supervised Mirati Therapies' $ 5.8 billion sale to Bristol Myers Sq...

Asarina to close after initiatives to companion Tourette's drug fail

.After connecting to much more than 200 providers to companion a Tourette syndrome therapy that show...